Cisplatin-based chemotherapy followed by surgery for malignant nonseminomatous germ cell tumor of mediastinum: One institution's experience

被引：1
作者：
Nakamura Y. [1 ]
Matsumura A. [1 ]
Katsura H. [1 ]
Sakaguchi M. [1 ]
Ito N. [1 ]
Kitahara N. [1 ]
Ose N. [1 ]
Kitaichi M. [2 ]
机构：
[1] Department of Surgery, National Hospital Organization, Kinkichuo Chest Medical Center, Sakai, Osaka 591-8555
[2] Department of Pathology, National Hospital Organization, Kinki-chuo Chest Medical Center, Osaka
来源：
General Thoracic and Cardiovascular Surgery | 2009年 / 57卷 / 7期
关键词：
Chemotherapy; Mediastinum; Nonseminomatous germ cell tumor; Serum tumor marker; Surgery;
D O I：
10.1007/s11748-008-0375-z
中图分类号：
学科分类号：
摘要：
Objective: The objective of this study was to evaluate the efficacy and safety of cisplatin-based chemotherapy followed by surgery for patients with a malignant nonseminomatous germ cell tumor (NSGCT) of the mediastinum. Methods: Ten patients with malignant NSGCTs received cisplatin-based induction chemotherapy and then underwent surgery. The clinicopathological characteristics of these 10 patients were examined retrospectively. Results: A partial response to induction chemotherapy was noted in eight patients and no response in two. The induction chemotherapy was tolerated well by all the patients. Each patient underwent complete surgical resection of the residual tumor following chemotherapy. A yolk sac tumor was detected in one patient and malignant teratoma along with a yolk sac tumor in one patient postoperatively. The overall survival of the 10 patients was 67% at 60 months of follow-up. The survival rate at 60 months was poorer for the patients whose resected specimens exhibited the presence of viable cells than for those whose specimens were free of viable cells. Conclusion: Postchemotherapy surgical resection of the residual tumor plays an integral role in the management of patients with NSGCT. The presence of viable tumor cells in the resected specimens is associated with poor survival. © 2009 The Japanese Association for Thoracic Surgery.
引用
收藏
页码：363 / 368
页数：5
相关论文
共 17 条
  • [11] International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers, J Clin Oncol, 15, pp. 594-603, (1997)
  • [12] Kesler K.A., Rieger K.M., Ganjoo K.N., Sharma M., Fineberg N.S., Einhorn L.H., Et al., Primary nonseminomatous germ cell tumors: The influence of postchemotherapy pathology on long-term survival after surgery, J Thorac Cardiovasc Surg, 118, pp. 692-701, (1999)
  • [13] Sakurai H., Asamura H., Suzuki K., Watanabe S., Tsuchiya R., Management of primary malignant germ cell tumor of the mediastinum, Jpn J Clin Oncol, 34, pp. 386-392, (2004)
  • [14] Kang C.H., Kim Y.T., Jheon S.H., Sung S.W., Kim J.H., Surgical treatment of malignant mediastinal nonseminomatous germ cell tumor, Ann Thorac Surg, 85, pp. 379-384, (2008)
  • [15] Motzer R.J., Bosl G.J., Chemotherapy for germ cell tumors, Urol Clin North Am, 14, pp. 389-8, (1987)
  • [16] Motzer R.J., Geller N.L., Tan C.C., Herr H., Morse M., Fair W., Et al., Salvage chemotherapy for patients with germ cell tumors: The Memorial Sloan Kettering Cancer Center experience (1979-1989), Cancer, 67, pp. 1305-1310, (1991)
  • [17] Kesler K.A., Rieger K.M., Hammoud Z.T., Kruter L.E., Perkins S.M., Turrentine M.W., Et al., A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors, Ann Thorac Surg, 85, pp. 371-378, (2008)
12